EP4703363A1 — Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof
Assigned to Shandong Luye Pharmaceutical Co Ltd · Expires 2026-03-04 · 0y expired
What this patent protects
The present disclosure relates to a salt form and crystal form of a thienopyrimidine compound, and a preparation method therefor and the use thereof. Specifically, provided are a salt form and crystal form of the compound of formula I, a preparation method therefor, and the use t…
USPTO Abstract
The present disclosure relates to a salt form and crystal form of a thienopyrimidine compound, and a preparation method therefor and the use thereof. Specifically, provided are a salt form and crystal form of the compound of formula I, a preparation method therefor, and the use thereof in the preparation of a drug as a GnRH receptor antagonist.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.